Abstract:Glioblastoma (GBM) is the highest grade of glioma for which no effective therapy is currently available. Despite extensive research in diagnosis and therapy, there has been no significant improvement in GBM outcomes, with a median overall survival continuing at a dismal 15–18 months. In recent times, glioblastoma stem cells (GSCs) have been identified as crucial drivers of treatment resistance and tumor recurrence, and GBM therapies targeting GSCs are expected to improve patient outcomes. We used a multistep in silico screening strategy to identify repurposed candidate drugs against selected therapeutic molecular targets in GBM with potential to concomitantly target GSCs. Common differentially expressed genes (DEGs) were identified through analysis of multiple GBM and GSC datasets from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). For identification of target genes, we selected the genes with most significant effect on overall patient survival. The relative mRNA and protein expression of the selected genes in TCGA control versus GBM samples was also validated and their cancer dependency scores were assessed. Drugs targeting these genes and their corresponding proteins were identified from LINCS database using Connectivity Map (CMap) portal and by in silico molecular docking against each individual target using FDA-approved drug library from the DrugBank database, respectively. The molecules thus obtained were further evaluated for their ability to cross blood brain barrier (BBB) and their likelihood of resulting in drug resistance by acting as p-glycoprotein (p-Gp) substrates. The growth inhibitory effect of these final shortlisted compounds was examined on a panel of GBM cell lines and compared with temozolomide through the drug sensitivity EC50 values and AUC from the PRISM Repurposing Secondary Screen, and the IC50 values were obtained from GDSC portal. We identified RPA3, PSMA2, PSMC2, BLVRA, and HUS1 as molecular targets in GBM including GSCs with significant impact on patient survival. Our results show GSK-2126458/omipalisib, linifanib, drospirenone, eltrombopag, nilotinib, and PD198306 as candidate drugs which can be further evaluated for their anti-tumor potential against GBM. Through this work, we identified repurposed candidate therapeutics against GBM utilizing a GSC inclusive targeting approach, which demonstrated high in vitro efficacy and can prospectively evade drug resistance. These drugs have the potential to be developed as individual or combination therapy to improve GBM outcomes.

Reversal Gene Expression Assessment for Drug Repurposing, a Case Study of Glioblastoma

A Computational Framework to Identify Biomarkers for Glioma Recurrence and Potential Drugs Targeting Them

Repurposing Ivermectin and ATRA as Potential Therapeutics for Glioblastoma Multiforme

Signature reversion of three disease‐associated gene signatures prioritizes cancer drug repurposing candidates

A Multistep In Silico Approach Identifies Potential Glioblastoma Drug Candidates via Inclusive Molecular Targeting of Glioblastoma Stem Cells

Abstract 3503: New generation drug development from in-silico identification to preclinical evaluation in glioblastoma

High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity

Multicellular biomarkers of drug resistance as promising targets for glioma precision medicine and predictors of patient survival

Pharmacogenomic Analysis of Combined Therapies against Glioblastoma Based on Cell Markers from Single-Cell Sequencing

Bioinformatics Analysis of High-Throughput Data to Validate Potential Novel Biomarkers and Small Molecule Drugs for Glioblastoma Multiforme

Metabolic modeling-based drug repurposing in Glioblastoma

Genome-Scale Metabolic Modeling of Glioblastoma Reveals Promising Targets for Drug Development

Antiretroviral Drug Repositioning for Glioblastoma

Dddr-17. A Facile High Throughput Drug Screening Platform Enables The Construction Of A Pharmaco-Proteogenomic Interaction Landscape In Glioblastoma

Identification of potential biomarkers and candidate small molecule drugs in glioblastoma

Relapse pathway of glioblastoma revealed by single-cell molecular analysis

Integration of Computational Pipeline to Streamline Efficacious Drug Nomination and Biomarker Discovery in Glioblastoma

Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets

Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma

Computational repurposing of oncology drugs through off‐target drug binding interactions from pharmacological databases

Challenges and advances in glioblastoma targeted therapy: the promise of drug repurposing and biomarker exploration